Hematology-Oncology Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.
Hematology-Oncology Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.
Semin Oncol Nurs. 2019 Oct;35(5):150931. doi: 10.1016/j.soncn.2019.08.010. Epub 2019 Aug 31.
OBJECTIVE: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS). DATA SOURCES: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events. CONCLUSION: Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research. Prompt recognition and management of the side effects of CAR T-cell therapy is pivotal to the safe outcomes of patients. As patients are treated with these novel therapies, additional recommendations and standards for treating CRS and neurotoxicity will occur. IMPLICATION FOR NURSING PRACTICE: Nursing plays a pivotal role in the CAR T patients' treatment course because they are the first line of defense in the care of these patients. Providers and patients both rely on nursing knowledge and training to recognize symptoms of CRS and neurotoxicity. With the early recognition of the signs and symptoms of CRS and neurotoxicity, nursing will help improve the outcomes of the patients receiving CAR T-cell therapy.
目的:讨论护士确保为细胞因子释放综合征(CRS)患者提供支持的当前建议和资源。
资料来源:使用关键词进行文献检索:细胞因子释放综合征、神经毒性、嵌合抗原受体(CAR)T 细胞、不良事件。
结论:嵌合抗原受体(CAR)T 细胞免疫疗法是一个不断发展和快速变化的研究领域。迅速识别和管理 CAR T 细胞治疗的副作用对于患者的安全结果至关重要。随着患者接受这些新疗法的治疗,将出现针对 CRS 和神经毒性的额外建议和标准。
对护理实践的意义:护理在 CAR T 患者的治疗过程中起着关键作用,因为她们是这些患者护理的第一道防线。提供者和患者都依赖护理知识和培训来识别 CRS 和神经毒性的症状。通过早期识别 CRS 和神经毒性的体征和症状,护理将有助于改善接受 CAR T 细胞治疗的患者的结局。
Semin Oncol Nurs. 2019-8-31
Semin Oncol Nurs. 2019-9-25
Semin Oncol Nurs. 2019-9-13
Expert Rev Hematol. 2019-3-18
J Am Coll Cardiol. 2019-12-24
Transplant Cell Ther. 2023-7
Zhonghua Xue Ye Xue Za Zhi. 2023-12-14
Intensive Care Med. 2024-9
Expert Opin Biol Ther. 2020-6
Biology (Basel). 2025-8-12
Front Immunol. 2025-2-24
Ann Med Surg (Lond). 2023-10-20